Arecor Therapeutics PLC Notice of Results
May 14 2024 - 5:17AM
RNS Regulatory News
RNS Number : 3611O
Arecor Therapeutics PLC
14 May 2024
Arecor Therapeutics
plc
("Arecor"
or the "Group")
NOTICE OF
RESULTS
Cambridge, UK, 14 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical
group advancing today's therapies to enable healthier lives,
will announce its final results for the year ended
31 December 2023 on Thursday 16 May 2024.
Sarah Howell, Chief Executive
Officer, and Manjit Rahelu, Chief Business Officer, will host an
in-person briefing for analysts at 11:00am BST on the day of the
results at the offices of Panmure Gordon, 40 Gracechurch St,
London, EC3V 0BT. There will also be a live webcast and conference
call with a Q&A session.
For more details or to attend the
briefing, please contact arecor@consilium-comms.com
-ENDS-
For
more information, please contact:
|
Arecor Therapeutics plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Susan Lowther, Chief Financial
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl
(Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
Tel: +44 (0) 20 7886 2500
|
|
WG
Partners LLP (Financial
Advisor)
Nigel Barnes, Satheesh
Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0) 203 705 9321
|
|
ICR
Consilium
|
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a
globally focused biopharmaceutical company transforming patient
care by bringing innovative medicines to market through the
enhancement of existing therapeutic products. By applying our
innovative proprietary technology platform, Arestat™, we are
developing an internal portfolio of proprietary products in
diabetes and other indications, as well as working with leading
pharmaceutical and biotechnology companies to deliver therapeutic
products. The Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our
website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORGCGDUUBBDGSS
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Nov 2023 to Nov 2024
